Cell Line Development Services for Meningioma
Meningioma is the most common form of primary brain tumor, accounting for approximately 30% of all brain tumors. It is primarily low-grade and may become cancerous over time, transforming from cells in the meninges that protect the brain and spinal cord. In vitro studies of the cellular functions and mechanisms of malignant meningiomas, as well as in vivo studies, are essential in the search for new therapeutic approaches for malignant tumors and the translation of basic research into clinical applications.
We offer services for meningioma cell line development
Alfa Cytology can culture stable malignant meningioma primary cells to isolate and culture meningioma cell lines of uniform cell quality. They are identified by immunofluorescence and other assays that match the characteristics of meningioma cells. We can also perform cell viability and cell morphology assays by MTT and bright-field microscopy and examine adhesion chemotaxis, and invasion by real-time cell analysis.
Successfully developed meningioma cell lines
| Cell lines |
- IOMM-Lee
- CH157-MN
- BEN-MEN-1
-
SF3061
|
Organism |
Homo sapiens (Human) |
| Tissue |
Brain |
| Morphology |
Epithelial |
| Culture properties |
Adherent |
STR identification of meningioma cell lines
During scientific research, the use of cross-contaminated or misidentified cells will lead to serious problems such as wrong research conclusions, non-reproducible results, and disastrous consequences of clinical therapy. STR genotyping can be used as the gold standard for cell identification.
The alleles on the STR gene seat can be distinguished by the difference in copy number of repetitive sequences in the PCR amplified region. We match the resulting STR typing results with STR data of cell lines from multiple databases to derive the name of the cell line to which the sample belongs or the cell line with possible cross-contamination. We can provide STR identification service for meningioma cell lines with reliable data and a short experimental cycle time.
- Cell species identification
- Cell recovery and culture
- Other cell identification-related services
Applications
- Establishment of intracranial graft retention tumor model in mice with malignant meningioma.
- Study of the mechanisms by which signaling pathways regulate the proliferation of malignant meningioma cells.
- Validation of the efficacy of monoclonal antibodies or other drugs specifically targeting meningiomas and other related drug evaluation.
- Study of the mechanisms driving the development and aggressive growth of meningiomas.
- Antiretroviral drug therapy studies.
Case Study - IOMM-Lee Xenograft Model
Model Introduction
The IOMM-Lee xenograft model is a clinically relevant preclinical platform for studying anaplastic meningioma biology and evaluating therapeutics. Derived from a human intraosseous malignant meningioma, the IOMM-Lee cell line exhibits aggressive growth, high proliferative capacity, and key histopathological features of anaplastic meningiomas, such as high cellularity, nuclear pleomorphism, necrosis, and conspicuous mitotic activity. This model is especially useful for investigating tumor-host interactions at the skull base, patterns of brain invasion, tumor hypoxia, and responses to alkylating agents like temozolomide.
Model Information
- Model: Meningioma Xenograft Model
- Animals: Nude Mice
- Weight: 18-20 g
Model Construction
The model is established by orthotopically implanting human IOMM-Lee malignant meningioma cells into the skull base region of athymic mice. Cell inoculum is 5×104 cells/mouse in 0.5 µL of Matrigel solution. Tumor growth is monitored non-invasively using bioluminescent imaging following lentiviral transduction of firefly luciferase.
Fig. 1 Workflow of IOMM-Lee xenograft model establishment. (Source: Alfa Cytology)
Model Data
- Tumorigenicity: IOMM-Lee cells demonstrate consistent and reproducible tumor formation in athymic mice, with 100% engraftment rate and localized growth at the skull base.
- Growth Kinetics: Tumor growth is progressive, with consistent survival times ranging from 17-21 days post-implantation. Histopathological analysis reveals skull invasion, brain invasion along perivascular tracts, and the emergence of hypoxia and necrosis by day 9 and day 12, respectively.
Fig. 2 Survival curves of IOMM-Lee xenografts. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Alfa Cytology offers a simple and easy-to-use method for isolating and culturing meningioma cells, and the isolated cells can be stably passaged to facilitate experimental studies on meningioma cell characteristics. The meningioma cell lines we have developed are good experimental tools for laboratory studies on the pathogenesis of meningioma-grade metastasis, and also provide a model for clinical studies on meningioma prevention. Please contact our staff to select the right cell line for your meningioma research.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
